Scientific Session News Today

Lerodalcibep, a third-generation PCSK9 inhibitor, reduced LDL by more than 50% vs placebo in patients with or at a high risk for CVD in the phase 3 LIBerate-HR trial.

Eli Lilly and Company will submit results of the study to support tirzepatide (Zepbound) for treatment of obstructive sleep apnea later this year.

In patients with STEMI and multivessel disease, FFR-guided complete nonculprit revascularization did not reduce events vs culprit lesion-only PCI in the FULL-REVASC trial.

The PROACT trial assessing enalapril in patients with cancer undergoing chemotherapy showed this approach did not affect cardiac function or the rate of cardiac injury.

Preventive PCI plus optimal medical therapy reduced cardiac events and death in patients with non–flow-limiting coronary plaques vs medical therapy.

Many people believe or have likened diabetes to a death sentence, that when one has it, it would be difficult to recover from or totally eliminate it. Diabetes Mellitus continues to be among the Top 5 causes of death in the Philippines. From January to May of last year, deaths…

A drug targeting mRNA essential for APO C-III production provided a 50% reduction in triglycerides in BRIDGE-TIMI 73a, the largest ever observed in a controlled trial.

The Minneapolis Heart Institute Foundation (MHIF) is presenting leading research focused on trends in ST-elevation myocardial infarction (STEMI), the most severe form of a heart attack, at the American College of Cardiology’s Annual Scientific Session (ACC.24), being held April 6-8 in Atltanta, GA. An analysis of nearly 8,000 STEMI patients over 20 years found the majority of STEMI occur in individuals without prior cardiovascular disease, and this prevalence is unchanged over time.

Alberto Foà, MD, PhD, discusses a PARAGON-HF analysis from ACC.24 examining treatment-related hypotension in people with HFmrEF/HFpEF.

Use of a microaxial flow pump led to a lower risk of death in patients with STEMI-related cardiogenic shock in the DanGer Shock trial, although with more adverse events.